X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs GLENMARK PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA GLENMARK PHARMA CIPLA/
GLENMARK PHARMA
 
P/E (TTM) x 43.6 13.6 319.6% View Chart
P/BV x 3.6 3.8 94.0% View Chart
Dividend Yield % 0.4 0.3 107.5%  

Financials

 CIPLA   GLENMARK PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
GLENMARK PHARMA
Mar-16
CIPLA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs6221,262 49.3%   
Low Rs458672 68.3%   
Sales per share (Unadj.) Rs181.9270.6 67.2%  
Earnings per share (Unadj.) Rs12.924.9 51.7%  
Cash flow per share (Unadj.) Rs29.334.4 85.2%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.40.2 179.0%  
Book value per share (Unadj.) Rs155.7151.3 102.9%  
Shares outstanding (eoy) m804.51282.16 285.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.6 83.1%   
Avg P/E ratio x42.038.9 108.0%  
P/CF ratio (eoy) x18.428.1 65.6%  
Price / Book Value ratio x3.56.4 54.3%  
Dividend payout %15.58.0 193.3%   
Avg Mkt Cap Rs m434,516272,778 159.3%   
No. of employees `00023.010.0 229.9%   
Total wages/salary Rs m26,33813,782 191.1%   
Avg. sales/employee Rs Th6,349.17,614.9 83.4%   
Avg. wages/employee Rs Th1,143.01,374.8 83.1%   
Avg. net profit/employee Rs Th449.3700.2 64.2%   
INCOME DATA
Net Sales Rs m146,30276,340 191.6%  
Other income Rs m2,287356 642.0%   
Total revenues Rs m148,58976,696 193.7%   
Gross profit Rs m24,75814,172 174.7%  
Depreciation Rs m13,2292,691 491.5%   
Interest Rs m1,5941,789 89.1%   
Profit before tax Rs m12,22210,048 121.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7983,028 59.4%   
Profit after tax Rs m10,3547,019 147.5%  
Gross profit margin %16.918.6 91.2%  
Effective tax rate %14.730.1 48.8%   
Net profit margin %7.19.2 77.0%  
BALANCE SHEET DATA
Current assets Rs m87,37059,096 147.8%   
Current liabilities Rs m33,08140,018 82.7%   
Net working cap to sales %37.125.0 148.5%  
Current ratio x2.61.5 178.8%  
Inventory Days Days8775 116.0%  
Debtors Days Days62119 52.3%  
Net fixed assets Rs m111,56739,075 285.5%   
Share capital Rs m1,609282 570.2%   
"Free" reserves Rs m123,64530,281 408.3%   
Net worth Rs m125,25442,703 293.3%   
Long term debt Rs m36,45424,873 146.6%   
Total assets Rs m209,532111,026 188.7%  
Interest coverage x8.76.6 131.0%   
Debt to equity ratio x0.30.6 50.0%  
Sales to assets ratio x0.70.7 101.5%   
Return on assets %5.77.9 71.9%  
Return on equity %8.316.4 50.3%  
Return on capital %8.517.5 48.5%  
Exports to sales %34.243.3 79.0%   
Imports to sales %8.37.4 112.3%   
Exports (fob) Rs m50,05033,044 151.5%   
Imports (cif) Rs m12,2035,672 215.1%   
Fx inflow Rs m51,06636,945 138.2%   
Fx outflow Rs m17,67861,066 28.9%   
Net fx Rs m33,388-24,122 -138.4%   
CASH FLOW
From Operations Rs m23,8243,449 690.8%  
From Investments Rs m-13,127-8,802 149.1%  
From Financial Activity Rs m-13,2396,986 -189.5%  
Net Cashflow Rs m-2,478934 -265.4%  

Share Holding

Indian Promoters % 16.0 48.3 33.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 6.9 176.8%  
FIIs % 23.7 34.4 68.9%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.5 249.5%  
Shareholders   161,166 56,727 284.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 23, 2017 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS